Skip to main content
×
×
Home

Effect of long-term nutraceutical and dietary supplement use on cognition in the elderly: a 10-year systematic review of randomised controlled trials

  • Nathan M. D’Cunha (a1) (a2), Ekavi N. Georgousopoulou (a1) (a2) (a3), Lakshika Dadigamuwage (a1), Jane Kellett (a1) (a2) (a3), Demosthenes B. Panagiotakos (a1) (a3), Jackson Thomas (a1) (a4), Andrew J. McKune (a2) (a5) (a6), Duane D. Mellor (a1) (a2) (a4) and Nenad Naumovski (a1) (a2) (a4)...
Abstract
Abstract

Nutraceuticals have generated interest as a way to mitigate the cognitive decline in older adults. The aim of this systematic review was to determine the evidence for these claims from the scientific literature in randomised, double-blinded, controlled trials (duration: ≥1 year; participants: n≥100; age(mean): ≥65 years). Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we searched four electronic databases (PubMed, Scopus, CINAHL and Web of Science) and identified twenty-five studies published between the 15·June·2006 and 14·June·2016. Interventions included B-vitamins, n-3 fatty acids, antioxidant vitamins and herbs. Of the B-vitamin studies, four found benefits to cognition with supplementation. The first of these B-vitamin studies, in individuals with mild cognitive impairment (n 266; duration=2 years), included benefit to executive function (P=0·015) and improvements in the Mini-Mental State Examination (MMSE) among participants with baseline homocysteine above 11·3 µmol/l (P<0·001). In the same sample, the second study found cognitive benefits of B-vitamins dependent on the higher baseline plasma n-3 fatty acid status. The third B-vitamin study (n 900; duration=2 years) reported improved performance in immediate (P=0·046) and delayed recall (P=0·013), whereas the fourth study (n 856; duration=2 years) reported slower rate of cognitive decline in the MMSE (P=0·05). One study investigating DHA treatment (n 402; duration=1·5 years) revealed the slower rate of cognitive change in apoE e4 non-carriers (P=0·03). As only five included studies revealed notable benefits, presently based on the specific compounds explored here, there is not compelling evidence to support the use nutraceuticals to improve cognition in the elderly. Future long-term trials of nutraceuticals should investigate interactions with lifestyle, blood biomarkers and genetic risk factors.

Copyright
Corresponding author
* Corresponding author: Dr N. Naumovski, fax +61 2 6201 5999, email nenad.naumovski@canberra.edu.au
References
Hide All
1. He W, Goodkind D & Kowal P (2016) An Aging World: 2015. International Population Reports . Washington, DC: U.S. Census Bureau.
2. Wasay M, Grisold W, Carroll W, et al. (2016) World Brain Day 2016: celebrating brain health in an ageing population. Lancet Neurol 15, 1008.
3. Ngandu T, Lehtisalo J, Solomon A, et al. (2015) A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet 385, 22552263.
4. Rountree SD, Chan W, Pavlik VN, et al. (2009) Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. Alzheimer’s Res Ther 1, 7.
5. Meguro M, Kasai M, Akanuma K, et al. (2008) Comprehensive approach of donepezil and psychosocial interventions on cognitive function and quality of life for Alzheimer’s disease: the Osaki-Tajiri Project. Age Ageing 37, 469473.
6. Takizawa C, Thompson PL, van Walsem A, et al. (2015) Epidemiological and economic burden of Alzheimer’s disease: a systematic literature review of data across Europe and the United States of America. J Alzheimer’s Dis 43, 12711284.
7. Siddiqui MJ, Min CS, Verma RK, et al. (2014) Role of complementary and alternative medicine in geriatric care: a mini review. Pharmacog Rev 8, 8187.
8. Harrington CR (2012) The molecular pathology of Alzheimer’s disease. Neuroimaging Clin N Am 22, 1122, vii.
9. Reitz C (2012) Alzheimer’s disease and the amyloid cascade hypothesis: a critical review. Int J Alzheimers Dis 2012, 11.
10. Willette AA, Bendlin BB, Starks EJ, et al. (2015) Association of insulin resistance with Cerebral glucose uptake in late middle-aged adults at risk for Alzheimer disease. JAMA Neurol 72, 10131020.
11. Naeini AM, Elmadfa I, Djazayery A, et al. (2014) The effect of antioxidant vitamins E and C on cognitive performance of the elderly with mild cognitive impairment in Isfahan, Iran: a double-blind, randomized, placebo-controlled trial. Eur J Nutr 53, 12551262.
12. Opara JA (2012) Activities of daily living and quality of life in Alzheimer disease. J Med Life 5, 162167.
13. Djernes JK (2006) Prevalence and predictors of depression in populations of elderly: a review. Acta Psychiatr Scand 113, 372387.
14. Sando SB, Melquist S, Cannon A, et al. (2008) APOE ε4 lowers age at onset and is a high risk factor for Alzheimer’s disease; a case control study from central Norway. BMC Neurol 8, 9.
15. Xu W, Tan L, Wang H-F, et al. (2015) Meta-analysis of modifiable risk factors for Alzheimer’s disease. J Neurol Neurosurg Psychiatry 86, 1299.
16. van de Rest O, Berendsen AAM, Haveman-Nies A, et al. (2015) Dietary patterns, cognitive decline, and dementia: a systematic review. Adv Nutr 6, 154168.
17. Canevelli M, Lucchini F, Quarata F, et al. (2016) Nutrition and dementia: evidence for preventive approaches? Nutrients 8, 144.
18. Mogendi JB, De Steur H, Gellynck X, et al. (2016) Consumer evaluation of food with nutritional benefits: a systematic review and narrative synthesis. Int J Food Sci Nutr 67, 355371.
19. Qato DM, Wilder J, Schumm LP, et al. (2016) Changes in prescription and over-the-counter medication and dietary supplement use among older adults in the United States, 2005 vs 2011. JAMA Intern Med 176, 473482.
20. Gahche J, Bailey R, Burt V, et al. (2011) Dietary supplement use among U.S. adults has increased since NHANES III (1988–1994). NCHS Data Brief, 18.
21. Petroczi A, Taylor G & Naughton DP (2011) Mission impossible? Regulatory and enforcement issues to ensure safety of dietary supplements. Food Chem Toxicol 49, 393402.
22. Gabriels G & Lambert M (2013) Nutritional supplement products: does the label information influence purchasing decisions for the physically active? Nutr J 12, 133.
23. Heuberger R (2012) Polypharmacy and food–drug interactions among older persons: a review. J Nutr Gerontol Geriatr 31, 325403.
24. Deldicque L & Francaux M (2016) Potential harmful effects of dietary supplements in sports medicine. Curr Opin Clin Nutr Metab Care 19, 439445.
25. Geller AI, Shehab N, Weidle NJ, et al. (2015) Emergency department visits for adverse events related to dietary supplements. N Engl J Med 373, 15311540.
26. Mursu J, Robien K, Harnack LJ, et al. (2011) Dietary supplements and mortality rate in older women: the Iowa Women’s Health Study. Arch Intern Med 171, 16251633.
27. Das L, Bhaumik E, Raychaudhuri U, et al. (2012) Role of nutraceuticals in human health. J Food Sci Technol 49, 173183.
28. Nasri H, Baradaran A, Shirzad H, et al. (2014) New concepts in nutraceuticals as alternative for pharmaceuticals. Int J Prev Med 5, 14871499.
29. Kalra EK (2003) Nutraceutical-definition and introduction. AAPS PharmSci 5, 2728.
30. Geleijnse JM, Giltay EJ & Kromhout D (2012) Effects of n-3 fatty acids on cognitive decline: a randomized, double-blind, placebo-controlled trial in stable myocardial infarction patients. Alzheimers Dement 8, 278287.
31. McDougall GJ, Austin-Wells V & Zimmerman T (2005) Utility of nutraceutical products marketed for cognitive and memory enhancement. J Holist Nurs 23, 415433.
32. Alzheimer’s Association (2017) Alternative treatments. http://www.alz.org/alzheimers_disease_alternative_treatments.asp (accessed February 2017).
33. Zandi PP, Anthony JC, Khachaturian AS, et al. (2004) Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol 61, 8288.
34. Moher D, Liberati A, Tetzlaff J, et al. (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6, e1000097.
35. Clarke R, Bennett D, Parish S, et al. (2014) Effects of homocysteine lowering with B vitamins on cognitive aging: meta-analysis of 11 trials with cognitive data on 22,000 individuals. Am J Clin Nutr 100, 657666.
36. Oulhaj A, Jernerén F, Refsum H, et al. (2016) Omega-3 fatty acid status enhances the prevention of cognitive decline by b vitamins in mild cognitive impairment. J Alzheimers Dis 50, 547557.
37. Ford AH, Flicker L, Alfonso H, et al. (2010) Vitamins B12, B6, and folic acid for cognition in older men. Neurology 75, 15401547.
38. Rainey-Smith SR, Brown BM, Sohrabi HR, et al. (2016) Curcumin and cognition: a randomised, placebo-controlled, double-blind study of community-dwelling older adults. Br J Nutr 115, 21062113.
39. Higgins JP & Green S (2011) Cochrane Handbook for Systematic Reviews of Interventions, vol. 4. Chichester: John Wiley & Sons.
40. Chew EY, Clemons TE, Agron E, et al. (2015) Effect of omega-3 fatty acids, lutein/zeaxanthin, or other nutrient supplementation on cognitive function: the AREDS2 randomized clinical trial. JAMA 314, 791801.
41. Grodstein F, O’Brien J, Kang JH, et al. (2013) Long-term multivitamin supplementation and cognitive function in men: a randomized trial. Ann Intern Med 159, 806-+.
42. McNeill G, Avenell A, Campbell MK, et al. (2007) Effect of multivitamin and multimineral supplementation on cognitive function in men and women aged 65 years and over: a randomised controlled trial. Nutr J 6, 10.
43. Rossom RC, Espeland MA, Manson JE, et al. (2012) Calcium and vitamin D supplementation and cognitive impairment in the Women’s Health Initiative. J Am Geriatr Soc 60, 21972205.
44. Aisen PS, Schneider LS, Sano M, et al. (2008) High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA 300, 17741783.
45. Dangour AD, Allen E, Clarke R, et al. (2015) Effects of vitamin B-12 supplementation on neurologic and cognitive function in older people: a randomized controlled trial. Am J Clin Nutr 102, 639647.
46. de Jager CA, Oulhaj A, Jacoby R, et al. (2012) Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial. Int J Geriatr Psychiatry 27, 592600.
47. Kwok T, Lee J, Law CB, et al. (2011) A randomized placebo controlled trial of homocysteine lowering to reduce cognitive decline in older demented people. Clin Nutr 30, 297302.
48. McMahon JA, Green TJ, Skeaff CM, et al. (2006) A controlled trial of homocysteine lowering and cognitive performance. N Engl J Med 354, 27642772.
49. Van Der Zwaluw NL, Dhonukshe-Rutten RAM, Van Wijngaarden JPV, et al. (2014) Results of 2-year vitamin B treatment on cognitive performance; secondary data from an RCT. Neurology 83, 21582166.
50. Walker JG, Batterham PJ, Mackinnon AJ, et al. (2012) Oral folic acid and vitamin B-12 supplementation to prevent cognitive decline in community-dwelling older adults with depressive symptoms – the Beyond Ageing Project: a randomized controlled trial. Am J Clin Nutr 95, 194203 [corrected] [published erratum appears in Am J Clin Nutr 2012 Aug;96(2):448].
51. Dangour AD, Allen E, Elbourne D, et al. (2010) Effect of 2-y n-3 long-chain polyunsaturated fatty acid supplementation on cognitive function in older people: a randomized, double-blind, controlled trial. Am J Clin Nutr 91, 17251732.
52. Quinn J, Raman R, Thomas R, et al. (2010) Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA 304, 19031911.
53. DeKosky ST, Williamson JD, Fitzpatrick AL, et al. (2008) Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA 300, 22532262.
54. Snitz BE, O’Meara ES, Carlson MC, et al. (2009) Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. JAMA 302, 26632670.
55. Dodge HH, Zitzelberger T, Oken BS, et al. (2008) A randomized placebo-controlled trial of Ginkgo biloba for the prevention of cognitive decline. Neurology 70, 18091817.
56. Grodstein F, Kang JH, Glynn RJ, et al. (2007) A randomized trial of beta carotene supplementation and cognitive function in men – the Physicians’ Health Study II. Arch Intern Med 167, 21842190.
57. Hu K, Riemersma-van der Lek RF, Patxot M, et al. (2016) Progression of dementia assessed by temporal correlations of physical activity: results from a 3.5-year, longitudinal randomized controlled trial. Sci Rep 6, 27742.
58. Turner RS, Thomas RG, Craft S, et al. (2015) A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology 85, 13831391.
59. Riemersma-van der Lek RF, Swaab DF, Twisk J, et al. (2008) Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial. JAMA 299, 26422655.
60. Vellas B, Coley N, Ousset PJ, et al. (2012) Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer’s disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol 11, 851859.
61. Veronese N, Stubbs B, Maggi S, et al. (2017) Low-dose aspirin use and cognitive function in older age: a systematic review and meta-analysis. J Am Geriatr Soc 65, 17631768.
62. Yetley EA (2007) Multivitamin and multimineral dietary supplements: definitions, characterization, bioavailability, and drug interactions. Am J Clin Nutr 85, 269S276S.
63. Scragg R, Stewart AW, Waayer D, et al. (2017) Effect of monthly high-dose vitamin d supplementation on cardiovascular disease in the vitamin d assessment study: a randomized clinical trial. JAMA Cardiol 2, 608616.
64. Smith AD, Smith SM, de Jager CA, et al. (2010) Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLOS ONE 5, e12244.
65. Kennedy OD (2016) B vitamins and the brain: mechanisms, dose and efficacy – a review. Nutrients 8, 68.
66. Yassine HN, Rawat V, Mack WJ, et al. (2016) The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer’s disease. Alzheimers Res Ther 8, 25.
67. Panagiotakos D (2014) A Mediterranean diet supplemented with olive oil or nuts reduces the incidence of major cardiovascular events in high-risk patients. BMJ Evid Based Med 19, 10.
68. Martinez-Lapiscina EH, Clavero P, Toledo E, et al. (2013) Virgin olive oil supplementation and long-term cognition: the Predimed-Navarra randomized, trial. J Nutr Health Aging 17, 544552.
69. Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, et al. (2006) Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol 63, 14021408.
70. Freund-Levi Y, Basun H, Cederholm T, et al. (2008) Omega-3 supplementation in mild to moderate Alzheimer’s disease: effects on neuropsychiatric symptoms. Int J Geriatr Psychiatry 23, 161169.
71. Ketz JS, Rodavich MC & Barnes KM (2013) Absorption of marine vs non-marine sources of EPA and DHA. FASEB J 27, 867.863.
72. Therapeutic Goods Administration (2009) Australian public assessment report for melatonin. Proprietary Product Name: Circadin. https://www.tga.gov.au/sites/default/files/auspar-circadin.pdf (accessed September 2017).
73. Nestor SM, Rupsingh R, Borrie M, et al. (2008) Ventricular enlargement as a possible measure of Alzheimer’s disease progression validated using the Alzheimer’s disease neuroimaging initiative database. Brain 131, 24432454.
74. Weinmann S, Roll S, Schwarzbach C, et al. (2010) Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. BMC Geriatr 10, 14.
75. Byers T (1999) What can randomized controlled trials tell us about nutrition and cancer prevention? CA Cancer J Clin 49, 353361.
76. Wang H, Naghavi M, Allen C, et al. (2016) Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388, 14591544.
77. Durga J, van Boxtel MP, Schouten EG, et al. (2007) Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial. Lancet 369, 208216.
78. Rundblad A, Holven KB, Ottestad I, et al. (2017) High-quality fish oil has a more favourable effect than oxidised fish oil on intermediate-density lipoprotein and LDL subclasses: a randomised controlled trial. Br J Nutr, 117 12911298.
79. Burton GW, Traber MG, Acuff RV, et al. (1998) Human plasma and tissue alpha-tocopherol concentrations in response to supplementation with deuterated natural and synthetic vitamin E. Am J Clin Nutr 67, 669684.
80. Lucock M & Yates Z (2005) Folic acid – vitamin and panacea or genetic time bomb? Nat Rev Genet 6, 235240.
81. Moore EM, Ames D, Mander AG, et al. (2014) Among vitamin B12 deficient older people, high folate levels are associated with worse cognitive function: combined data from three cohorts. J Alzheimers Dis 39, 661668.
82. Schiepers OJG, Harris SE, Gow AJ, et al. (2012) APOE E4 status predicts age-related cognitive decline in the ninth decade: longitudinal follow-up of the Lothian Birth Cohort 1921. Mol Psychiatry 17, 315324.
83. Liu C-C, Kanekiyo T, Xu H, et al. (2013) Apolipoprotein E and Alzheimer disease: risk, mechanisms, and therapy. Nat Rev Neurol 9, 106118.
84. B RC, Hare DJ, Lind M, et al. (2017) The APOE epsilon4 Allele Is Associated with Lower Selenium Levels in the Brain: Implications for Alzheimer’s Disease. ACS Chemical Neurosci 8, 14591464.
85. Minihane AM (2016) Impact of genotype on EPA and DHA status and responsiveness to increased intakes. Nutrients 8, 123.
86. Lucock MD, Martin CE, Yates ZR, et al. (2014) Diet and our genetic legacy in the recent anthropocene: a Darwinian perspective to nutritional health. J Evid Based Complementary Altern Med 19, 6883.
87. Meyer BJ, Onyiaodike CC, Brown EA, et al. (2016) Maternal plasma DHA levels increase prior to 29 days post-LH surge in women undergoing frozen embryo transfer: a prospective, observational study of human pregnancy. J Clin Endocrinol Metab 101, 17451753.
88. Farrer LA, Cupples LA, Haines JL, et al. (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278, 13491356.
89. Hathcock J (2001) Dietary supplements: how they are used and regulated. J Nutr 131, 1114s1117s.
90. Guallar E, Stranges S, Mulrow C, et al. (2013) Enough is enough: Stop wasting money on vitamin and mineral supplements. Ann Intern Med 159, 850851.
91. Bjelakovic G, Nikolova D & Gluud C (2013) Antioxidant supplements to prevent mortality. JAMA 310, 11781179.
92. Abner EL, Schmitt FA, Mendiondo MS, et al. (2011) Vitamin E and all-cause mortality: a meta-analysis. Curr Aging Sci 4, 158170.
93. Macpherson H, Pipingas A & Pase MP (2013) Multivitamin-multimineral supplementation and mortality: a meta-analysis of randomized controlled trials. Am J Clin Nutr 97, 437444.
94. Li K, Kaaks R, Linseisen J, et al. (2012) Vitamin/mineral supplementation and cancer, cardiovascular, and all-cause mortality in a German prospective cohort (EPIC-Heidelberg). Eur J Nutr 51, 407413.
95. Fortmann SP, Burda BU, Senger CA, et al. (2013) Vitamin and mineral supplements in the primary prevention of cardiovascular disease and cancer: an updated systematic evidence review for the U.S. preventive services task force. Ann Intern Med 159, 824834.
96. Onakpoya IJ & Heneghan CJ (2017) The efficacy of supplementation with the novel medical food, Souvenaid, in patients with Alzheimer’s disease: a systematic review and meta-analysis of randomized clinical trials. Nutr Neurosci 20, 219227.
97. Soininen H, Visser P, Kivipelto M, et al. (2016) A clinical trial investigating the effects of fortasyn connect (Souvenaid) in prodromal Alzheimer’s disease: results of the LipiDiDiet study. Neurobiol Aging 39, S23.
98. Andrieu S, Guyonnet S, Coley N, et al. (2017) Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurol 16, 377389.
99. Yassine HN & Schneider LS (2017) Lessons from the Multidomain Alzheimer Preventive Trial. Lancet Neurol 16, 585586.
100. Pouchieu C, Andreeva VA, Peneau S, et al. (2013) Sociodemographic, lifestyle and dietary correlates of dietary supplement use in a large sample of French adults: results from the NutriNet-Sante cohort study. Br J Nutr 110, 14801491.
101. Schwartz B (2014) New criteria for supplementation of selected micronutrients in the era of nutrigenetics and nutrigenomics. Int J Food Sci Nutr 65, 529538.
102. Beckett EL, Martin C, Boyd L, et al. (2017) Reduced plasma homocysteine levels in elderly Australians following mandatory folic acid fortification; a comparison of two cross-sectional cohorts. J Nutr Intermed Metab 8, 1420.
103. Baum L, Lam CW, Cheung SK, et al. (2008) Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol 28, 110113.
104. Mori K, Inatomi S, Ouchi K, et al. (2009) Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. Phytother Res 23, 367372.
105. Solomon TM, Leech J, deBros GB, et al. (2016) A randomized, double-blind, placebo controlled, parallel group, efficacy study of alpha BRAIN(R) administered orally. Hum Psychopharmacol 31, 135143.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

British Journal of Nutrition
  • ISSN: 0007-1145
  • EISSN: 1475-2662
  • URL: /core/journals/british-journal-of-nutrition
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords:

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 3
Total number of PDF views: 64 *
Loading metrics...

Abstract views

Total abstract views: 410 *
Loading metrics...

* Views captured on Cambridge Core between 9th January 2018 - 22nd January 2018. This data will be updated every 24 hours.